Equity Overview
Price & Market Data
Price: $1.29
Daily Change: -$0.0297 / 2.30%
Range: $1.26 - $1.35
Market Cap: $24,912,940
Volume: 104,032
Performance Metrics
1 Week: -2.99%
1 Month: 3.17%
3 Months: -4.41%
6 Months: -21.21%
1 Year: 14.05%
YTD: -28.18%
Company Details
Employees: 16
Sector: Health technology
Industry: Biotechnology
Country: Israel
Details
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.